Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Contraception
Contraceptive efficacy and safety of DMPA-SC reviewed
December 16th, 2004
Researchers review the contraceptive efficacy and safety of DMPA-SC in a recent issue of the journal Contraception. According to a study from the United States, "DMPA-SC 104 mg/0.65 mL is a new, low-dose subcutaneous (SC) formulation of Depo-Provera contraceptive injection (150 mg/mL medroxyprogesterone acetate injectable suspension) that provides efficacy, safety and immediacy of onset equivalent to Depo-Provera intramuscular (IM) injection. Two large, open-label, Phase 3 studies assessed the one-year contraceptive efficacy, safety and patient satisfaction with DMPA-SC administered every three months (12-13 weeks)." "Zero pregnancies were...
Source: Women's Health Weekly (2004-12-16)
|
